What are the key implications of the positive Phase 3 results for VEGF Trap-Eye?

The positive Phase 3 results are highly significant as they indicate VEGF Trap-Eye is a strong potential competitor to existing treatments for wet AMD. Meeting the primary endpoint of non-inferiority, especially with a less frequent dosing regimen (every two months), suggests it could offer similar efficacy with improved patient convenience. This paves the way for regulatory submissions in major markets, potentially leading to future revenue streams.

What is the financial impact of the termination of the AstraZeneca/MedImmune license agreement?

The termination means Regeneron will no longer receive the $20 million annual non-refundable payments from this specific license. However, Regeneron retains the right to receive mid-single digit royalties on any future sales of products developed by MedImmune/AstraZeneca using the VelocImmune technology. While the upfront payments cease, the long-term royalty potential remains, though the immediate financial impact involves the loss of guaranteed annual revenue.

Why did Regeneron file a lawsuit against Genentech?

Regeneron initiated litigation against Genentech to obtain a declaratory judgment confirming that its activities related to its VEGF Trap do not infringe on specified Genentech patents. This proactive legal step aims to clarify the intellectual property landscape and protect Regeneron's commercialization efforts for its VEGF Trap technology.

How does VEGF Trap-Eye compare to the current standard of care, ranibizumab?

In the Phase 3 studies, VEGF Trap-Eye demonstrated non-inferiority to ranibizumab in maintaining or improving vision. A secondary endpoint also showed a statistically significant greater mean improvement in visual acuity for one specific dose regimen of VEGF Trap-Eye compared to ranibizumab. Both treatments showed a generally favorable and balanced safety profile.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 22, 2010, reporting significant developments. The company announced highly positive top-line results from two pivotal Phase 3 studies (VIEW 1 and VIEW 2) for its wet age-related macular degeneration (wet AMD) treatment, VEGF Trap-Eye (aflibercept ophthalmic solution), in collaboration with Bayer HealthCare. Notably, all tested regimens of VEGF Trap-Eye, including one dosed every two months, met the primary endpoint of non-inferiority to the current standard of care, ranibizumab dosed monthly, in maintaining or improving vision over 52 weeks. This suggests a potentially strong competitor to existing treatments, with regulatory submissions planned for early 2011. In separate but also material news, Regeneron disclosed the termination of its six-year non-exclusive license agreement with AstraZeneca (now MedImmune) concerning its VelocImmune technology. While this agreement generated $20 million annually, the termination is effective in 90 days. Regeneron will continue to be eligible for mid-single digit royalties on any future antibody products discovered by MedImmune/AstraZeneca using the technology. The company also initiated litigation against Genentech seeking a declaratory judgment of non-infringement related to its VEGF Trap intellectual property.

Key Highlights

1Positive top-line results from Phase 3 VIEW 1 and VIEW 2 studies for VEGF Trap-Eye in wet AMD patients were announced.
2VEGF Trap-Eye, in all tested regimens (including every two months dosing), met the primary endpoint of non-inferiority compared to ranibizumab (Lucentis) dosed monthly for vision maintenance.
3Regeneron and Bayer plan to submit marketing approval applications for VEGF Trap-Eye in the U.S. and Europe in the first half of 2011.
4A secondary endpoint showed a statistically significant greater mean improvement in visual acuity for VEGF Trap-Eye 2mg monthly versus ranibizumab 0.5mg monthly in the VIEW 1 study.
5The termination of the non-exclusive license agreement with AstraZeneca/MedImmune for VelocImmune technology was disclosed, effective in 90 days.
6Regeneron is entitled to mid-single digit royalties on future sales of products discovered by MedImmune/AstraZeneca using VelocImmune.
7Regeneron filed a lawsuit against Genentech seeking a declaratory judgment of non-infringement of specific patents related to its VEGF Trap.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Agreement Terminated (Nov 22, 2010)

Summary

Key Highlights

Frequently Asked Questions